setmelanotide · Medicine question

From what age is Imcivree (setmelanotide) indicated for obesity and hunger associated with Bardet-Biedl syndrome?

Name: From what age is Imcivree (setmelanotide) indicated for obesity and hunger associated with Bardet-Biedl syndrome?
Published: 2026-11-08T02:00:34.330Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Imcivree (setmelanotide) is indicated from 2 years of age for treating obesity and controlling hunger associated with genetically confirmed Bardet-Biedl syndrome, including in adults.

Sources for this answer

IMCIVREE 10 mg/ml solution for injectionRhythm Pharmaceutical UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 8Document updated 16 March 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about setmelanotide